{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:58:37Z","timestamp":1787169517640,"version":"build-2736575974"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Psoriasis, a chronic, immune-mediated skin disorder, has systemic manifestations as well as an ample negative impact on the quality of life (QOL) of the patient. An abnormal proliferation of keratinocyte and dermal infiltration by immune cells is a characteristic feature. It involves components of both innate and adaptive immunity, and the interaction of T cells with macrophages. Keratinocytes and dendritic cells are mediated by the secreted cytokines. This study was taken up to look into changes at the molecular level that occur during the expression of three cytokines namely tumour necrosis factor\u2013alpha (TNF\u03b1), interleukin 17A (IL-17A) and interleukin 6 (IL-6) in Indian patients with psoriasis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A case-control study was conducted with samples from 15 psoriasis vulgaris patients and 10 healthy control subjects. Clinical parameters were recorded. Blood samples were analysed for peripheral blood messenger ribonucleic acid (mRNA) expression of TNF\u03b1, IL-17A and IL-6 using real-time polymerase chain reaction (RT-PCR).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The mRNA expression of TNF\u03b1, IL-17A and IL-6 in psoriasis patients were increased as compared to that in normal subjects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>The elevated levels of Interleukins indicates a systemic inflammatory process that is akin to the cutaneous inflammation. This study indicates that the targeted therapies against these cytokines are likely to be beneficial in Indian psoriasis patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/idoj.idoj_306_21","type":"journal-article","created":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T00:02:05Z","timestamp":1646265725000},"page":"229-233","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":13,"title":["Relevance of Inflammatory Cytokine mRNA Expression of Tumour Necrosis Factor- Alpha (TNF \u03b1), Interleukin 17A (IL 17A) and Interleukin 6 (IL 6) in Indian Patients with Psoriasis"],"prefix":"10.4103","volume":"13","author":[{"given":"Saiqa R.","family":"Shah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadiya B.","family":"Shaikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yashodhar P.","family":"Bhandary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaheena","family":"Yassir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manjunath M.","family":"Shenoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-8-20240828","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1111\/bjd.12230","article-title":"Is the prevalence of psoriasis increasing.A 30-year follow-up of a population-based cohort?","volume":"168","author":"Danielsen","year":"2013","journal-title":"Br J Dermatol"},{"key":"R2-8-20240828","first-page":"97","article-title":"Current developments in the immunology of psoriasis","volume":"93","author":"Graen","year":"2020","journal-title":"Yale J Biol Med"},{"key":"R3-8-20240828","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3389\/fphar.2020.00117","article-title":"Pathogenesis of chronic plaque psoriasis and its intersection with cardio-metabolic comorbidities","volume":"11","author":"Gisondi","year":"2020","journal-title":"Front Pharmacol"},{"key":"R4-8-20240828","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.3390\/ijms20061475","article-title":"Psoriasis pathogenesis and treatment","volume":"20","author":"Rendon","year":"2019","journal-title":"Int J Mol Sci"},{"key":"R5-8-20240828","doi-asserted-by":"crossref","first-page":"e12946","DOI":"10.1111\/sji.12946","article-title":"The TNF\/IL-23\/IL-17 axis-Head-to-head trials comparing different biologics in psoriasis treatment","volume":"92","author":"Ten Bergen","year":"2020","journal-title":"Scand J Immunol"},{"key":"R6-8-20240828","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2340\/0001555572165168","article-title":"Interleukin-6 in normal skin and psoriasis","volume":"72","author":"Castells-Rodellas","year":"1992","journal-title":"Acta Derm Venereol"},{"key":"R7-8-20240828","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1111\/bjd.13146","article-title":"A case of tumour necrosis factor-\u03b1 inhibitor- and rituximab-induced plantar pustular psoriasis that completely resolved with tocilizumab","volume":"171","author":"Jayasekera","year":"2014","journal-title":"Br J Dermatol"},{"key":"R8-8-20240828","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.jaad.2014.01.897","article-title":"Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: Results of a double-blind, randomized, placebo-controlled, phase-III study","volume":"71","author":"Krupashankar","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"R9-8-20240828","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1517\/17425255.2014.970165","article-title":"Pharmacogenetics of etanercept: Role of TNF-\u03b1 gene polymorphisms in improving its efficacy","volume":"10","author":"Murdaca","year":"2014","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"R10-8-20240828","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sj.gene.6364351","article-title":"Psoriasis: Genetic associations and immune system changes","volume":"8","author":"Liu","year":"2007","journal-title":"Genes Immun"},{"key":"R11-8-20240828","first-page":"199","article-title":"Laboratory protocols for the quantitation of cytokines by bioassay using cytokine responsive cell lines","volume":"211","author":"Mire-Sluis","year":"1998","journal-title":"J Immunol Methods"},{"key":"R12-8-20240828","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1128\/CDLI.7.6.920-924.2000","article-title":"Measurement of cytokine secretion, intracellular protein expression, and mRNA in resting and stimulated peripheral blood mononuclear cells","volume":"7","author":"Sullivan","year":"2000","journal-title":"Clin Diagn Lab Immunol"},{"key":"R13-8-20240828","first-page":"115","article-title":"Infliximab for the treatment of plaque psoriasis","volume":"2","author":"Gall","year":"2008","journal-title":"Biologics"},{"key":"R14-8-20240828","first-page":"13","article-title":"Serum visfatin, adiponectin, and tumor necrosis factor alpha (TNF-\u03b1) levels in patients with psoriasis and their correlation with disease severity","volume":"24","author":"Sereflican","year":"2016","journal-title":"Acta Dermato Venerol Croat"},{"key":"R15-8-20240828","first-page":"675","article-title":"Cytokines of the IL-17 family in psoriasis","volume":"18","author":"Lauffer","year":"2020","journal-title":"J Dtsch Dermatol Ges"},{"key":"R16-8-20240828","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.3390\/ijms21041275","article-title":"Interleukin-17A and keratinocytes in psoriasis","volume":"21","author":"Furue","year":"2020","journal-title":"Int J Mol Sci"},{"key":"R17-8-20240828","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1365-2249.2012.04618.x","article-title":"Experimentally induced psoriatic lesion associates with interleukin (IL)-6 in mast cells and appearance of dermal cells expressing IL-33 and IL-6 receptor","volume":"169","author":"Suttle","year":"2012","journal-title":"Clin Exp Immunol"},{"key":"R18-8-20240828","doi-asserted-by":"crossref","first-page":"964069","DOI":"10.1155\/2014\/964069","article-title":"IL-6 as a druggable target in psoriasis: Focus on pustular variants","volume":"2014","author":"Saggini","year":"2014","journal-title":"J Immunol Res"}],"container-title":["Indian Dermatology Online Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/idoj.idoj_306_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:07:36Z","timestamp":1787166456000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/idoj.idoj_306_21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/idoj.idoj_306_21","relation":{},"ISSN":["2229-5178"],"issn-type":[{"value":"2229-5178","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]}}}